Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel Meeting Abstract

  

Authors:	Scher, H. I.; Heller, G.; Molina, A.; Kheoh, T. S.; Attard, G.; Moreira, J.; Sandhu, S. K.; Parker, C.; Logothetis, C.; McCormack, R. T.; Fizazi, K.; Anand, A.; Danila, D. C.; Fleisher, M.; Olmos, D.; Haqq, C. M.; De Bono, J. S.
Abstract Title:	Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel
Meeting Title:	47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	29
Issue:	18 Suppl.
Meeting Dates:	2011 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2011-06-20
Language:	English
ACCESSION:	WOS:000208865800020
PROVIDER:	wos
DOI:	10.1200/jco.2011.29.18_suppl.lba4517
Notes:	Meeting Abstract: LBA4517 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/141568